Regarding the increase in tumor burden in GPR55 WT mice, it should be noted that cancer patients can paradoxically respond with increased tumor progression to immune checkpoint inhibitor therapy (hyperprogressive disease) (62, 63), something that has been now also reported for advanced pancreatic cancer (64). This evidence concerns the gene GPR55 and familial pancreatic carcinoma.